Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 03

1044P - UniTope & TraCR: Universal tagging and tracking system for TCR-T cells integrated directly in the TCR constant region

Date

14 Sep 2024

Session

Poster session 03

Topics

Tumour Immunology;  Translational Research;  Targeted Therapy;  Molecular Oncology;  Cell-Based Therapy;  Immunotherapy

Tumour Site

Presenters

Kirsty Crame

Citation

Annals of Oncology (2024) 35 (suppl_2): S674-S711. 10.1016/annonc/annonc1596

Authors

K. Crame1, K. Mishra2, J. Ogonek2, D.J. Schendel1, B. Lösch2

Author affiliations

  • 1 Clinical Development, Medigene GmbH, 82152 - Martinsried (Planegg)/DE
  • 2 Technology & Innovation, Medigene GmbH, 82152 - Martinsried (Planegg)/DE

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 1044P

Background

For product development, GMP production, quality control for product release and immune monitoring of patient samples, three methods are typically used to identify rTCR expression in TCR-T populations: (1) detection of an extra tag that is co-expressed with the rTCR; (2) binding of antibodies specific for TCR Vß-chains, or (3) rTCR binding of peptide-HLA multimers. The latter two approaches must be tailored for each rTCR and high-quality reagents may not be readily available.

Methods

Using bioinformatics and 3D modeling of TCRs, novel synthetic epitopes were designed and inserted at different positions in multiple rTCR sequences. Internally tagged rTCRs were assessed for surface expression, functionality and target specificity, as well as for binding of an antibody (TraCR) detecting the synthetic epitopes of different length.

Results

Identifying a unique, synthetic epitope (UniTope) and optimal insertion sites localized in the rTCR constant regions permitted highly specific detection by the TraCR antibody. The UniTope & TraCR combination unambiguously distinguishes rTCRs expressed in recipient T cells from all endogenous TCRs found in PBL. The integrated UniTope tag exclusively binds TraCR antibody, and not alter functionality, established safety profiles or expression levels of any of the assessed rTCRs.

Conclusions

UniTope & TraCR is a universal detection system for rTCRs easy to adapt for multi-parameter flow cytometry. Seamless integration of UniTope in any rTCR structure bypasses need for co-expression of a separate gene sequence to universally tag rTCR-expressing T cells. Providing a standardized detection system, UniTope & TraCR simplifies supply and validation of quality control assays for TCR-T therapies covering all rTCRs, providing precise information for drug product dosing. It allows easy visualization, isolation and enrichment of TCR-T cells for direct study. GMP-grade TraCR can be applied for drug product enrichment and potentially also to trace TCR-T cell localization and persistence in vivo, supporting immune monitoring in patients. The UniTope & TraCR system is a high precision technology that facilitates optimized development of TCR-T therapies.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.